Trails Edge Capital Partners LP Takes Position in 4D Molecular Therapeutics, Inc. $FDMT

Trails Edge Capital Partners LP purchased a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,227,917 shares of the company’s stock, valued at approximately $29,631,296,000. 4D Molecular Therapeutics comprises 4.7% of Trails Edge Capital Partners LP’s investment portfolio, making the stock its 5th biggest holding.

Several other hedge funds have also recently modified their holdings of FDMT. Legal & General Group Plc purchased a new position in 4D Molecular Therapeutics in the 2nd quarter valued at $59,000. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics during the 3rd quarter worth $41,000. Daiwa Securities Group Inc. raised its position in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth $77,000. Finally, Martingale Asset Management L P lifted its stake in shares of 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after acquiring an additional 1,303 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $15.72 on Wednesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $16.93. The company has a 50-day simple moving average of $11.88 and a 200-day simple moving average of $10.21. The company has a market capitalization of $868.37 million, a PE ratio of -5.98 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. Equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FDMT has been the topic of a number of recent analyst reports. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Finally, B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

Insider Buying and Selling

In other news, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the sale, the insider directly owned 871,737 shares in the company, valued at approximately $8,760,956.85. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 200,496 shares of company stock valued at $2,240,244. Insiders own 7.90% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.